Human TRAIL R2/TNFRSF10B Affinity Purified Polyclonal Ab (25 UG)【科瑞奥博】

产品中心

当前位置：首页>产品中心

Human TRAIL R2/TNFRSF10B Affinity Purified Polyclonal Ab (25 UG)

货号： AF631-SP 基本售价： 1378.1 元规格： -

产品信息

概述
货号	AF631-SP
别名	CD262 antigen; CD262; death domain containing receptor for TRAIL/Apo-2L; Death receptor 5; DR5; DR5TRICK2B; Fas-like protein; KILLER/DR5; KILLERapoptosis inducing protein TRICK2A/2B; TNF-related apoptosis-inducing ligand receptor 2; TNFRSF10B; TRAIL receptor 2; TRAIL-R2apoptosis inducing receptor TRAIL-R2; TRAILR2cytotoxic TRAIL receptor-2; TRICK2; TRICK2A; TRICKB; tumor necrosis factor receptor superfamily member 10B; tumor necrosis factor receptor superfamily, member 10b; tumor necrosis factor receptor-like protein ZTNFR9; ZTNFR9
全称	TRAIL Receptor 2
反应种属	Human
应用	Western Blot(1 µg/mL)
目标/特异性	Detects human TRAIL R2/TNFRSF10B in direct ELISAs and Western blots. In direct ELISAs, approximately 10% cross-reactivity with recombinant human (rh) TRAIL R1 and rhTRAIL R4 is observed, and less than 1% cross-reactivity with rhTRAIL R3 is observed.
使用方法	Western Blot: 1 µg/mL Agonist Activity: Measured by its ability to induce apoptosis on Jurkat human acute T cell leukemia cells. The ED₅₀ for this effect is typically 0.05 - 0.2 μg/mL.
来源	Polyclonal Goat IgG
产品组分

性能
供应商	R&D Systems
Entrez Gene IDs	8795 (Human); 21933 (Mouse)
应用文献
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions. Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma. Authors: Kim, Seong Mu, Woo, Ji Sun, Jeong, Chang Hy, Ryu, Chung He, Jang, Jae-Deog, Jeun, Sin-Soo Stem Cells Transl Med, 2014;3(2):172-82. Species: Human Sample Type: Cell Lysates Application: WB Trichostatin A sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by down-regulation of c-FLIPL via inhibition of EGFR pathway. Authors: Park SJ, Kim MJ, Kim HB, Sohn HY, Bae JH, Kang CD, Kim SH Biochem. Pharmacol., 2009;77(8):1328-36. Species: Human Sample Type: Cell Lysates Application: WB Down-regulation of FoxO-dependent c-FLIP expression mediates TRAIL-induced apoptosis in activated hepatic stellate cells. Authors: Park SJ, Sohn HY, Yoon J, Park SI Cell. Signal., 2009;21(10):1495-503. Species: Human Sample Type: Whole Cells Application: Flow Sensitization of imatinib-resistant CML cells to TRAIL-induced apoptosis is mediated through down-regulation of Bcr-Abl as well as c-FLIP. Authors: Park SJ, Kim MJ, Kim HB, Kang CD, Kim SH Biochem. J., 2009;420(1):73-81. Species: Human Sample Type: Whole Cells Application: Flow TRAIL recombinant adenovirus triggers robust apoptosis in multidrug-resistant HL-60/Vinc cells preferentially through death receptor DR5. Authors: Wu CH, Kao CH, Safa AR Hum. Gene Ther., 2008;19(7):731-43. Species: Human Sample Type: Whole Cells Application: Neut Arsenic trioxide sensitizes human glioma cells, but not normal astrocytes, to TRAIL-induced apoptosis via CCAAT/enhancer-binding protein homologous protein-dependent DR5 up-regulation. Authors: Kim EH, Yoon MJ, Kim SU, Kwon TK, Sohn S, Choi KS Cancer Res., 2008;68(1):266-75. Species: Human Sample Type: Whole Cells Application: Flow Downmodulation of dimethyl transferase activity enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in prostate cancer cells. Authors: Festuccia C, Gravina GL, DAlessandro AM, Millimaggi D, Di Rocco C, Dolo V, Ricevuto E, Vicentini C, Bologna M Int. J. Oncol., 2008;33(2):381-8. Species: Human Sample Type: Cell Lysates Application: WB Differential response of p53 and p21 on HDAC inhibitor-mediated apoptosis in HCT116 colon cancer cells in vitro and in vivo. Authors: Zopf S, Neureiter D, Bouralexis S, Abt T, Glaser KB, Okamoto K, Ganslmayer M, Hahn EG, Herold C, Ocker M Int. J. Oncol., 2007;31(6):1391-402. Species: Human Sample Type: Cell Lysates Application: WB P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5. Authors: Park SJ, Wu CH, Choi MR, Najafi F, Emami A, Safa AR Biochem. Pharmacol., 2006;72(3):293-307. Species: Human Sample Type: Whole Cells Application: Neut Acquired resistance to TRAIL-induced apoptosis in human ovarian cancer cells is conferred by increased turnover of mature caspase-3. Authors: Lane D, Cote M, Grondin R, Couture MC, Piche A Mol. Cancer Ther., 2006;5(3):509-21. Species: Human Sample Type: Whole Cells Application: WB Death receptors, Fas and TRAIL receptors, are involved in human osteoclast apoptosis. Authors: Roux S, Lambert-Comeau P, Saint-Pierre C, Lepine M, Sawan B, Parent JL Biochem. Biophys. Res. Commun., 2005;333(1):42-50. Species: Human Sample Type: Whole Tissue Application: IHC Paraffin-embedded Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen-activated protein kinases and phosphatidylinositol 3-kinase/Akt. Authors: Morel J, Audo R, Hahne M, Combe B J. Biol. Chem., 2005;280(16):15709-18. Species: Human Sample Type: Whole Cells Application: Flow Absence of caspase 8 and high expression of PED protect primitive neural cells from cell death. Authors: Ricci-Vitiani L, Pedini F, Mollinari C, Condorelli G, Bonci D, Bez A, Colombo A, Parati E, Peschle C, De Maria R J. Exp. Med., 2004;200(10):1257-66. Species: Human Sample Type: Whole Cells Application: Flow Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) decoy receptor TRAIL-R3 is up-regulated by p53 in breast tumor cells through a mechanism involving an intronic p53-binding site. Authors: Ruiz de Almodovar C, Ruiz-Ruiz C, Rodriguez A, Ortiz-Ferron G, Redondo JM, Lopez-Rivas A J. Biol. Chem., 2004;279(6):4093-101. Species: Human Sample Type: Cell Lysates Application: WB Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21(waf1). Authors: Chopin V, Slomianny C, Hondermarck H, Le Bourhis X Exp. Cell Res., 2004;298(2):560-73. Species: Human Sample Type: Cell Lysates Application: WB Regulation of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Burkitt's lymphoma cell lines. Authors: Mouzakiti A, Packham G Br. J. Haematol., 2003;122(1):61-9. Species: Human Sample Type: Cell Lysates Application: WB An antibody against DR4 (TRAIL-R1) in combination with doxorubicin selectively kills malignant but not normal prostate cells. Authors: Voelkel-Johnson C Cancer Biol. Ther., 2003;2(3):283-90. Species: Human Sample Type: Whole Cells Application: Neut Interferon-alpha sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 upregulation and NF-kappa B inactivation. Authors: Shigeno M, Nakao K, Ichikawa T, Suzuki K, Kawakami A, Abiru S, Miyazoe S, Nakagawa Y, Ishikawa H, Hamasaki K, Nakata K, Ishii N, Eguchi K Oncogene, 2003;22(11):1653-62. Species: Human Sample Type: Whole Cells Application: Flow Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and TNF-alpha promote the NF-kappaB-dependent maturation of normal and leukemic myeloid cells. Authors: Secchiero P, Milani D, Gonelli A, Melloni E, Campioni D, Gibellini D, Capitani S, Zauli G J. Leukoc. Biol., 2003;74(2):223-32. Species: Human Sample Type: Whole Cells Application: Neut Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sequentially upregulates nitric oxide and prostanoid production in primary human endothelial cells. Authors: Zauli G, Pandolfi A, Gonelli A, Di Pietro R, Guarnieri S, Ciabattoni G, Rana R, Vitale M, Secchiero P Circ. Res., 2003;92(7):732-40. Species: Human Sample Type: Whole Cells Application: Flow Inflammatory cytokine regulation of TRAIL-mediated apoptosis in thyroid epithelial cells. Authors: Bretz JD, Mezosi E, Giordano TJ, Gauger PG, Thompson NW, Baker JR Cell Death Differ., 2002;9(3):274-86. Species: Human Sample Type: Whole Cells Application: Flow Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Authors: Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D, Hideshima T, Treon SP, Munshi NC, Richardson PG, Anderson KC Oncogene, 2002;21(37):5673-83. Species: Human Sample Type: Whole Cells Application: Flow
纯化方式	Antigen Affinity-purified
免疫原	Mouse myeloma cell line NS0-derived recombinant human TRAIL R2/TNFRSF10B Ala54-Glu182 Accession # Q6FH58
内毒素水平	<0.10 EU per 1 μg of the antibody by the LAL method.
生物活性	Measured by its ability to induce apoptosis on Jurkat human acute T cell leukemia cells. The ED₅₀ for this effect is typically 0.05 - 0.2 μg/mL.
标记	Unconjugated
溶解方法	Reconstitute at 0.2 mg/mL in sterile PBS.
背景	Human TRAIL R2, also called DR5 and TRICK 2 is a type 1, TNF R family, membrane protein which is a receptor for TRAIL (APO2 ligand). In the new TNF superfamily nomenclature, TRAIL R2 is referred to as TNFRSF10B. TRAIL R2 cDNA encodes a 440 amino acid residue precursor protein containing extracellular cysteine-rich domains, a transmembrane domain and a cytoplasmic death domain. Among TNF receptor family proteins, TRAIL R2 is most closely related to TRAIL R1/DR4, sharing 55% amino acid sequence identity. Binding of trimeric TRAIL to TRAIL R2 induces apoptosis. The induction of apoptosis likely requires oligomerization of the receptor. The human TRAIL R2/Fc chimera neutralizes the ability of TRAIL to induce apoptosis. Besides TRAIL R2, an additional TRAIL R1/DR4, which tranduces apoptosis signaling, and two TRAIL decoy receptors, which antagonize TRAIL-induced apoptosis, have been reported.
运输条件	Blue Ice
存放说明	4℃
参考文献	Chaudhary, P.M. et al. (1997) Immunity 7:821. Walczak, H. et al. (1997) EMBO J. 16:5386. Golstein, P. (1997) Curr. Biol. 7:R750.

参考图片

Detection of Human TRAIL R2/TNFRSF10B by Western Blot. Western blot shows lysates of HepG2 human hepatocellular carcinoma cell line. PVDF membrane was probed with 1 µg/mL of Human TRAIL R2/TNFRSF10B Antigen Affinity-purified Polyclonal Antibody (Catalog # AF631) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF019). A specific band was detected for TRAIL R2/TNFRSF10B at approximately 45 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 8.